Filing Flows › CytomX Therapeutics (CTMX) › Q3 2026 › vs Q3 2025
CytomX Therapeutics (CTMX) Q3 2026 vs Q3 2025 (year over year)
CytomX Therapeutics's revenue fell $4.3M (-72%) from $6.0M in Q3 2025 to $1.7M in Q3 2026.
CytomX Therapeutics, Q3 2026: revenue $1.7M (-72% year over year), net loss $20.0M, operating cash flow $16.6M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 951.4% | -258.6% | +1210.0 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $1.7M | $6.0M | −$4.3M | -72% |
| Other income, net | $3.6M | $1.6M | $2.0M | +123% |
| Net loss | $20.0M | $14.2M | $5.8M | +41% |
| Costs & expenses | $25.3M | $21.8M | $3.5M | +16% |
| Operating costs | $25.2M | $21.7M | $3.5M | +16% |
| Income tax | $61K | $58K | $3K | +5% |
| Research & development | $16.5M | $15.3M | $1.2M | +8% |
| General & admin | $8.7M | $6.4M | $2.3M | +36% |
| Operating cash sources | $36.6M | −$1.3M | $38.0M | — |
| Share-based compensation | $2.8M | $1.4M | $1.5M | +105% |
| Working capital & other | $33.8M | −$2.7M | $36.5M | — |
| Net loss absorbed | $20.0M | $14.2M | $5.8M | +41% |
| Operating cash flow | $16.6M | −$15.5M | $32.2M | — |
| Free cash flow (OCF − capex) | $16.1M | −$15.4M | $31.5M | — |
| Capital expenditures | $589K | −$127K | $716K | — |
Questions
How much did CytomX Therapeutics's revenue grow year over year in Q3 2026?
CytomX Therapeutics's revenue fell $4.3M (-72%) from $6.0M in Q3 2025 to $1.7M in Q3 2026.